Top-News

Ipsen S.A. ADR News

Aktie
WKN:  A1J2CW ISIN:  US4626292050 US-Symbol:  IPSEY
30,40 €
+0,20 €
+0,66%
07:57:38 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-

Ipsen S.A. ADR News

23.04.24 - PR Newswire
Ipsen und Skyhawk Therapeutics geben Zusammenarbeit bei der Erforschung seltener neurologischer Erkrankungen durch RNA-Targeting bekannt
Ipsen und Skyhawk Therapeutics geben Zusammenarbeit bei der Erforschung seltener neurologischer Erkrankungen durch RNA-​Targeting bekannt PR Newswire
22.04.24 - PR Newswire
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases PR Newswire
22.04.24 - PR Newswire
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases PR Newswire
02.04.24 - PR Newswire
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire
13.11.23 - PR Newswire
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC) PR ...
13.11.23 - PR Newswire
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC) PR ...
09.01.23 - PR Newswire
SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc.
SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc. PR Newswire
19.11.21 - PR Newswire
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing PR Newswire
01.04.21 - PR Newswire
Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen PR Newswire
02.03.21 - PR Newswire
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen PR Newswire
26.03.20 - PR Newswire
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing PR Newswire
16.03.20 - PR Newswire
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020 PR Newswire
10.03.20 - PR Newswire
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020 PR Newswire
05.06.19 - PR Newswire
Ipsen's Dysport® (Clostridium Botulinum Type a Toxin-haemagglutinin Complex) Becomes First and Only Botulinum Toxin Type A to be Granted a Licence Update for Administration by Healthcare Professionals, Such as Physiotherapists, in the UK
Ipsen's Dysport® (Clostridium Botulinum Type a Toxin-​haemagglutinin Complex) Becomes First and Only Botulinum Toxin Type A to be Granted a Licence Update for Administration ...
05.06.19 - PR Newswire
Ipsen's Dysport® (Clostridium Botulinum Type a Toxin-haemagglutinin Complex) Becomes First and Only Botulinum Toxin Type A to be Granted a Licence Update for Administration by Healthcare Professionals, Such as Physiotherapists, in the UK
Ipsen's Dysport® (Clostridium Botulinum Type a Toxin-​haemagglutinin Complex) Becomes First and Only Botulinum Toxin Type A to be Granted a Licence Update for Administration ...
19.11.18 - PR Newswire
Ipsen Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
Ipsen Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference PR Newswire
06.11.18 - PR Newswire
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 14th and 15th, 2018
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 14th and 15th, 2018 PR Newswire
14.03.17 - PR Newswire
Ipsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Patients with Cervical Dystonia and Adult Upper Limb Spasticity
Ipsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Patients with Cervical Dystonia and Adult Upper Limb Spasticity ...
08.01.17 - PR Newswire
Merrimack Concludes Strategic Review; Announces Plan to Divest Assets and Sharpen Strategic Focus
Merrimack Concludes Strategic Review; Announces Plan to Divest Assets and Sharpen Strategic Focus Company to Sell ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up ...
22.12.16 - PR Newswire
Ipsen Amends Licensing Agreement with Exelixis to Commercialize and Develop Cabozantinib in Canada
Ipsen Amends Licensing Agreement with Exelixis to Commercialize and Develop Cabozantinib in Canada Canada NewsWire

Newssuche

Videos

newspaper
17.05.24 -5,85%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »